Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

SLXNBearishCorporate Developmentsnews

High materiality7/10

Silexion Pricing Public Offering to Raise $2.5M to Fund SIL204

Aug 11, 2026, 8:03 PM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

New equity issuance dilutes existing holders and can pressure share price ahead of close; warrants exercisable immediately add further dilution pressure. Similar small-cap biotech fundraises often depress stock until close or until milestones are met.

AI summary

What happened, with direct paths to the underlying reporting

Silexion Therapeutics priced a public offering of 3,846,161 ordinary shares and 3,846,161 Series E warrants at $0.65 per share, aiming for about $2.5 million in gross proceeds with closing expected around August 13, 2026. Proceeds will fund SIL204 Phase 2/3 trials and general corporate needs. The deal creates immediate dilution and a near-term price sensitivity as investors await the closing.

Silexion prices 3.846M shares and 3.846M warrants at $0.65.
Closing expected around Aug 13, 2026; gross proceeds about $2.5M.
Funds to advance SIL204 trial and general corporate purposes.
Warrants exercisable immediately; placement agent is H.C. Wainwright.
Dilution risk and Nasdaq listing considerations for SLXN.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.